. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Breast Cancer Res Treat. 2018 Mar 22;170(2):405–414. doi: 10.1007/s10549-018-4761-7

Table 4.

Stratified analysis of treatment initiation and breast cancer-specific mortality according to Hispanic ethnicity among incident invasive breast cancer cases for whom treatment was indicated by the National Comprehensive Cancer Network (NCCN) guidelines.

Received Treatment Indicated by NCCN Guidelines (Strata)	Hispanic Subcohort		Non-Hispanic White Subcohort

	Contra-Indications	Therapy Eligible	Contra-Indications	Therapy Eligible	Stratum-Specific Hispanic Survival Hazard Ratio^c
	N %^a	N %^b	N %^a	N %^b	Stratum-Specific Hispanic Survival Hazard Ratio^c
Chemotherapy
Yes		80 (84.2)		183 (81.3)	1.5 (1.0–2.3)
No	23 (19.7)	15 (15.8)	92 (29.3)	42(18.7)	1.4 (0.2–8.9)
Radiation
Yes		99 (89.2)		298 (91.1)	1.7 (1.1–2.4)
No	7 (6.0)	12 (10.8)	16 (4.7)	29 (8.9)	2.4 (0.8–7.0)
Endocrine Therapy
Yes		66 (89.2)		212 (85.8)	1.9 (1.1–3.4)
No	19 (20.6)	8 (10.8)	40 (14.0)	35 (14.2)	6.4 (0.8–49.4)

Abbreviations: NCCN – National Comprehensive Cancer Network

Percent of all women eligible for therapy according to NCCN guidelines.

Percent of all eligible women after those with contraindications were omitted.

Adjusted for age, tumor size (National Comprehensive Cancer Network (NCCN) guideline categories < 1 cm, 1–<3 cm, 3–<5 cm, and ≥5 cm, chest wall/skin) positive lymph nodes (0, 1–3, 4+), tumor grade (1, 2, 3/4), estrogen receptor status, progesterone receptor status, Her2 status, and Hispanic ethnicity.